Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mirum Pharmaceuticals, Inc.
Age
13–45
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide signed informed consent/assent. Where local regulations permit inclusion of participants deemed unable to provide informed consent, a legally authorized representative must provide informed consent on the participant's behalf, and the participant must provide assent if applicable.
Male, 13-45 years of age (inclusive)
Weight ≥30 kg and BMI between 18 and 36 kg/m2 (inclusive) at the screening visit
Diagnosis of FXS with a molecular genetic ≥200 CGG repetitions .
Able to perform the PVT and ORRT of the NIH-TCB
Have a consistent caregiver(s) who is willing and able to be present regularly and reliably with the participant
Able to swallow tablets or capsules
You may not be if
History of or current medical condition other than FXS and related issues that would place the participant at higher risk from study participation
Clareo Health | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
